Background

Unexplained persistent breathlessness in patients with difficult asthma despite multiple treatments is a common clinical problem. Cardiopulmonary exercise testing (CPX) may help identify the mechanism causing these symptoms, allowing appropriate management.
Methods
This was a retrospective analysis of patients attending a specialist-provided service for difficult asthma who proceeded to CPX as part of our evaluation protocol. Patient demographics, lung function, and use of health care and rescue medication were compared with those in patients with refractory asthma. Medication use 6 months following CPX was compared with treatment during CPX.
Results
Of 302 sequential referrals, 39 patients underwent CPX. A single explanatory feature was identified in 30 patients and two features in nine patients: hyperventilation (n = 14), exercise-induced bronchoconstriction (n = 8), submaximal test (n = 8), normal test (n = 8), ventilatory limitation (n = 7), deconditioning (n = 2), cardiac ischemia (n = 1). Compared with patients with refractory asthma, patients without "pulmonary limitation" on CPX were prescribed similar doses of inhaled corticosteroid (ICS) (median, 1,300 µg [interquartile range (IQR), 800-2,000 µg] vs 1,800 µg [IQR, 1,000-2,000 µg]) and rescue oral steroid courses in the previous year (median, 5
vs 5 [1] [2] [3] [4] [5] [6] 
oxygen consumption
The diagnosis of asthma is usually straightforward, and most patients respond to standard doses of inhaled medication. Approximately 5% to 10% of adult patients have "difficult asthma," described as a failure to achieve symptom control despite prescribed treatment at step 4 of the GINA (Global Initiative for Asthma) guidelines. [1] , [2] Observational studies have suggested that after detailed systematic evaluation, approximately 50% of patients referred with difficult-to-treat asthma do not have refractory disease but have multiple other mechanisms for persistent symptoms. [3] , [4] , [5] Dysfunctional breathing was the most common alternative diagnosis, [3] , [4] and in another small series of patients, labeled as having "steroid resistant" asthma, hyperventilation was the most common condition identified as the mechanism of breathlessness and lack of steroid response. [6] These studies support detailed systematic evaluation of this population, including a review of the diagnosis of asthma and examination of the precise mechanism of symptoms. [2] Some patients, despite systematic evaluation, continue to have persistent symptoms that appear out of keeping with other clinical parameters of their asthma. This subgroup of patients poses a significant clinical challenge. Cardiopulmonary exercise testing (CPX) is a dynamic physiologic overview that identifies the mechanism of breathlessness in multiple clinical settings, including unexplained breathlessness. [7] , [8] , [9] , [10] , [11] , [12] , [13] The aim of this study was to examine the utility of CPX in defining the cause of persistent symptoms in subjects with difficult asthma.
Study Design and Population
This study was a retrospective analysis of patients attending the Northern Ireland Regional Difficult Asthma Service between February 2002 and August 2008, to identify the number of subjects progressing to and outcome of CPX. All tests were performed as part of our routine evaluation, and, thus, approval from our regional ethics committee was not required. Patients are referred to our clinic if they have persisting symptoms despite treatment at step 4 or 5 of the GINA guidelines and undergo a detailed systematic evaluation protocol as previously described, including medication adherence assessment. [3] , [14] Subjects with a discrepancy between their persistent unexplained symptoms and their detailed clinical history, physical examination, pulmonary function tests, airway inflammatory indices, and radiologic imaging progress to CPX. We examined patient demographics, lung function, medication and health-care use, anxiety, depression, and quality-of-life scores [15] , [16] and compared this to data for well-characterized patients fulfilling the American Thoracic Society (ATS) criteria for refractory asthma from our difficult asthma database. [17] We also assessed patients prescribed medication 6 months after CPX and compared this to their treatment regimen at the time of CPX referral.
Exercise Testing Materials
Exercise testing was performed using a breath-by-breath computerized exercise system, VMax 229 (Sensor Medics; Yorba Linda, California), a 12-lead ECG system, Cardiosys (Marquette; GE Medical Systems; Louisville, Kentucky) and a Marquette Series 2000 treadmill (Marquette; GE Medical Systems) with a grade range of 0% to 25% and speed range of 0 to 22 km/h. The VMax 229 exercise system uses a hot wire ventilometer to measure ventilation and was calibrated for volume with a 3-L syringe over a wide range of flows before each test. A paramagnetic oxygen analyzer and an infrared CO 2 analyzer were calibrated before each test with an automated three-point gas calibration procedure.
Exercise Testing Methods
Tests were carried out in an air-conditioned laboratory at a constant temperature of 22°C. Pre-exercise spirometry was performed according to ATS/European Respiratory Society guidelines. [18] , [19] Obstructive lung function was defined as a FEV 1 /FVC standard residual ≤ -1.64 (lower 90% confidence limit). [20] Following spirometry, the equipment was attached to the subject for at least 2 min before testing began to ensure a regular breathing pattern had been established, while in the standing position. A standardized exponential exercise protocol, [21] modified standardized exponential exercise protocol, [22] , [23] or modified Naughton [24] exercise protocol was performed, depending on the individual self-reported exercise tolerance of each subject, until exhaustion. Subjects were questioned on the reason for terminating the test. BP was measured at rest, at 3-min intervals during exercise, as close as possible to peak exercise, and at 2-min intervals during recovery. Postexercise spirometry was carried out at 1, 3, 5, 10, 15, and 20 min after the test.
Exercise Data Analysis and Interpretation
Exercise data were plotted as time-weighted 10-s averages. Peak oxygen consumption ( O 2 ) was defined as the average O 2 achieved during the final 30 s of exercise. The anaerobic threshold was determined using the V-slope method by two experienced observers blinded to the protocol. Two experienced observers also reviewed the data obtained from each exercise test and identified the features present using the definitions in Table 1 . The definitions have been drawn mainly from the ATS/American College of Chest Physicians guidelines, [7] with some additional features taken from Wasserman et al [25] and Cooper and Storer. [26] AT = anaerobic threshold; CaI = cardiac ischemia; CPX = cardiopulmonary exercise testing; EIB = exercise-induced bronchoconstriction; HR = heart rate; HV = hyperventilation; MVV = maximal voluntary ventilation; O 2 = oxygen; PETCO 2 = end-tidal PCO 2 ; RER = respiratory exchange ratio; SpO 2 = oxygen saturation; E/ CO 2 = ventilatory equivalent for CO 2 ; VL = ventilatory limitation; O 2 = oxygen consumption.
Statistical Methods
All data were analyzed using Statistical Package for Social Sciences, version 16 (SPSS; Chicago, Illinois). Data are presented as mean ± SD or median and interquartile range (IQR), with between-group comparisons made using independent t testing or Mann Whitney U tests as appropriate. Nominal variables were examined using χ 2 analysis. A P value < .05 was considered significant. (Table 2) . From the remaining referrals, 112 (37%) had refractory asthma, [17] 187 patients (62%) had asthma that stabilized with step 3/4 therapy, and four patients had nonasthma-related deaths. Subjects who underwent CPX had a mean FEV 1 of 2.37 ± 0.71 L (84% predicted ± 19% predicted), FVC 3.30 ± 0.81 L (98% predicted ± 14% predicted), and 10 of the 39 had airflow obstruction. The cardiopulmonary profile of the subjects who underwent CPX is displayed in Table 3 . Table 1 legend for expansion of other abbreviations.
The CPX diagnostic outcomes are shown in Table 4 . Of the 39 subjects studied, 30 had a single explanatory feature identified and nine patients had two features present. CPX identified a cause for the symptoms of 26 subjects (67%), leaving 13 patients (eight with a normal test, five with a submaximal test alone) with no pulmonary or cardiac cause for their symptoms detected. Hyperventilation was the most common feature identified, occurring in 14 subjects (36%). One patient exhibited evidence of clinically "silent" cardiac ischemia. Of the 10 patients with pre-exercise airflow obstruction, four had evidence of exercise-induced bronchoconstriction (EIB), two reached ventilatory limitation (VL) alone, one reached a ventilatory limit and had evidence of cardiac ischemia, one had evidence of hyperventilation, one performed a submaximal test, and one had a normal exercise test. Eleven subjects (28%) had evidence of pulmonary limitation defined as VL and/or EIB. 
More than one feature was identified in some individual patients (eg, 14 subjects had HV and of these one also had EIB and three had SM). No individual subject displayed more than two features. DC = deconditioning; NT = normal test; SM = submaximal test. See Table 1 legend for expansion of the other abbreviations.
a HV+EIB = 1 subject had HV and EIB b 5 SM+SM = 5 subjects had SM alone (no other feature was identified in each of the subjects CPX).
When subjects with a nonpulmonary mechanism for terminating CPX (n = 28) were compared with subjects with well-characterized refractory asthma, [17] lung function was significantly better in subjects who underwent CPX. Notably, the requirement for rescue steroids and dose of inhaled corticosteroids (ICSs) were not different; however, patients with refractory asthma were more likely to be receiving maintenance oral corticosteroids (Table 5 ). Although at the time of study 112 patients were found to have refractory asthma following detailed evaluation, only 95 consented to inclusion in our difficult asthma database. 
Outcome Post-CPX
Six months following CPX, patients with no evidence of pulmonary limitation had their medication reduced with no loss of symptom control; ICS dose was significantly reduced (pre-CPX median beclomethasone dipropionate [BDP] equivalent, 1,300 µg [IQR, 800-2,000 µg] vs post-CPX median BDP equivalent, 800 µg [IQR, 400-1,000 µg]; P < .001) and additional medication withdrawn in seven further subjects (theophylline, n = 2; leukotriene receptor antagonists, n = 3; long-acting β-agonist, n = 1; oral steroids, n = 1). In subjects with EIB or VL, ICS doses remained unchanged (pre-CPX median BDP equivalent, 2,000 µg [IQR, 1,200-2,000]; post-CPX median BDP equivalent, 2,000 µg [IQR, 1,200-2,000]), and additional therapies were introduced in eight subjects (theophylline, n = 4; leukotriene receptor antagonist, n = 3; oral steroids, n = 1).
In a population with difficult asthma, despite systematic multidisciplinary assessment, some patients have persistent symptoms that are out of keeping with their clinical parameters, and it remains unclear if their limitation is due to asthma. In this study we report the utility of CPX, undertaken as part of a protocolized evaluation of patients referred to a difficult asthma clinic to more precisely define the mechanism of persisting symptoms. In doing so, we have demonstrated a heterogeneous patient population and response to exercise. We also establish that identifying alternative mechanisms for breathlessness not related to asthma on CPX facilitates the reduction of administered asthma therapy.
CPX identified an explanatory cause for the symptoms of more than two-thirds of the subjects and excluded a significant underlying cardiac or pulmonary process as an explanation of the symptoms in the remaining patients. Of the causes highlighted, VL was identified in 18% of subjects. VL occurs when a subject approaches or reaches their ventilatory capacity at maximum exercise and is only likely to transpire when ventilatory capacity is reduced. [26] Four of the subjects with VL had EIB, whereas fixed airflow obstruction was present in the other three. Importantly, even in the three subjects with fixed airflow obstruction, the exercise distance at CPX was substantially greater than exercise capacity described at the clinic; thus, CPX was useful in objectively quantifying limitation in this group. Subjects with VL had more obstructive lung function than the rest of the cohort. One patient who reached their ventilatory limit also had evidence of cardiac ischemia despite having no history of chest pain. This subject did, however, have two cardiovascular risk factors: hypertension and a positive family history. The identification of abnormalities in both cardiovascular and pulmonary function demonstrates the versatility of CPX and the valuable clinical information it provides.
EIB was evident in 21% of subjects, supporting persistent ongoing symptoms due to asthma. This is useful clinical information in a situation in which the mechanism of symptoms may be in doubt and supports more aggressive management of underlying asthma. In all of these cases, asthma treatment was modified accordingly with add-on therapies (theophylline, or leukotriene receptor antagonist) introduced; a trial of maintenance oral corticosteroid therapy was given to one patient, and two patients using maintenance oral steroids progressed to a trial of a steroid-sparing agent. Confirmation that symptoms are due to asthma by CPX, in cases of clinical uncertainty, allows therapeutic increases to be made with greater confidence.
Physical deconditioning or relative unfitness has been described as impairment in the ability of exercising skeletal muscle to extract and use oxygen from the blood. [26] These features were identified in only two patients, which was surprising given the association of deconditioning with chronic pulmonary disease. [27] However, the young age of our sample and lack of comorbidities may partially account for this. It has been suggested that a vicious cycle results from disabling symptoms leading to physical inactivity, deconditioning, and worsening symptoms of exercise limitation. [28] This mechanism of disproportionate breathlessness, although present in our population, does not appear common.
Hyperventilation due to abnormal ventilatory control resulting in high ventilatory equivalents and low end-tidal PCO 2 was the most common feature identified in our population, with more than one-third of subjects showing these features. This abnormal ventilatory control can result in respiratory alkalosis and account for the symptoms of breathlessness, paresthesia, and dizziness. The frequency of hyperventilation in the group progressing to CPX again highlights the association between asthma and hyperventilation. Previous studies in subjects with difficult asthma have reported hyperventilation as the major cause of persisting symptoms, [3] , [4] , [6] and other studies have reported a high prevalence in subjects with milder disease. [29] , [30] , [31] A Glasgow study in patients with moderate to severe asthma demonstrated that only 10 out of 17 patients with a Nijmegen score consistent with a diagnosis of hyperventilation had evidence of this on exercise testing. [32] Taken together, these studies suggest that persistent symptoms of breathlessness in asthma are not uncommonly due to hyperventilation and that exercise testing is useful in identifying and confirming if this is present.
Submaximal physiologic values for an incremental exercise test are a result of suboptimal effort. [26] This may occur subconsciously due to poor motivation or may be a feature of certain psychologic disturbances. However, some subjects may use suboptimal effort to deliberately imply a decreased exercise capacity for secondary gain. These benefits may be financial, social, or psychologic in nature. In our group, a significant proportion of patients who performed a submaximal test also had evidence of hyperventilation during exercise (38%). It is possible that the physiologic effects of hyperventilation were responsible for the symptoms that led to the early cessation of the incremental exercise test. Twenty percent of subjects had a normal exercise test, which allowed an explanation to the patient that they have a normal exercise performance and that their breathlessness is physiologically normal, and subsequently this led to a reduction in therapy.
When we compared patients with nonpulmonary limitation on CPX to subjects with refractory asthma, lung function was significantly different, which was expected, as persistent symptoms inconsistent with static lung function are part of the clinical algorithm leading to CPX. However, similar doses of inhaled steroids and courses of rescue steroid therapy requirements were seen in both groups. In the absence of results from CPX, we believe this reflects overtreatment in our nonpulmonary limitation group and suggests that persistent nonasthma-related symptoms are managed with increasing asthma treatment. This is supported by the significant reduction of ICS dose and the withdrawal of add-on therapies following CPX in this group. CPX allows a more precise analysis of the mechanism of breathlessness and permits appropriate reduction of medication and the targeting of treatment to the cause of breathlessness.
We acknowledge that our study is retrospective and required subjective clinical interpretation to initiate CPX investigation in the patients. However, this decision was made following an objective systematic protocol [3] resulting in detailed patient phenotyping, therefore limiting any potential for bias. Our interpretations are based on the definitions provided in Table 2 , but we recognize that these definitions are open to discussion. However, in terms of usefulness in identifying a nonasthmatic alternative mechanism for symptoms in patients with difficult asthma, they appear to be useful in guiding therapeutic changes.
In summary, in an unselected population with difficult asthma, when systematically evaluated, multiple mechanisms for persisting symptoms are consistently reported. We have shown that CPX is a useful tool to objectify the degree of exertional limitation and more precisely define the mechanism of persistent symptoms. It can confirm exertional limitation due to asthma where it is not clinically apparent but also demonstrate other factors contributing to persisting symptoms, such as hyperventilation and deconditioning, and we would argue for CPX to be included in systematic evaluation protocols for difficult asthma.
